Hichi Pharmaceutical's Iodixanol API Approved for Market

2024/09/09

/uploads/image/2024/09/06/contrast-media-products-20240906-1.jpg

Iodixanol is the active pharmaceutical ingredient for iodixanol injection, a contrast agent used for intrathecal contrast, cardiovascular angiography, and intravenous urography. Its mechanism of action involves the absorption of X-rays by iodine in blood vessels or tissues, resulting in image display.

This time, Hichi Pharmaceutical's iodixanol active pharmaceutical ingredient obtained the "Chemical Active Pharmaceutical Ingredient Marketing Authorization Approval Notice." This not only enriches Hichi Pharmaceutical's active pharmaceutical ingredient variety and enhances its market competitiveness but also promotes the steady growth of Hichi Pharmaceutical's API sales business. Additionally, it will expand the depth and breadth of the company's integration of APIs and formulations in the field of contrast agents, creating favorable conditions for expanding the company's competitive advantage and market share in the contrast agent field.

Hichi Pharmaceutical's Iodixanol API Approved for Market

Beilu Pharma's Iohexol Injection Won the Bid in the Fifth round of National Centralized Drug Procurement

Knowledge About Non Ionic Contrast Medium

CPhl China 2023 Invitation

Beilu Pharmaceutical Obtains Drug Registration Certificate for Pramoxine Hydrochloride Sustained Release Tablets

Beilu Pharmaceutical Officially Acquires Tianyuan Pharmaceutical, Continues to Advance the Strategic Layout of Traditional Chinese Medicine

Good News: Beilu Pharmaceutical's Jiu Wei Zhenxin Granules Included in 20 Industry Guidelines Consensus Teaching Materials